Inovio sought to develop and market a coronavirus vaccine in the early years of the pandemic, though efforts were unsuccessful and the stock has lost significant market value. The FDA has accepted Inovio's biologics license application (BLA) for INO-3107 for review under the Accelerated Approval Program, with a PDUFA target date of October 30. The company's DNA platform represents its core competitive advantage, though commercialization faces challenges related to the proprietary Cellectra device delivery mechanism.
Cyborg Score Rationale
Inovio faces significant obstacles, and the stock will likely continue to drop over the medium term, with shares potentially worthless in five years. The company has encountered several regulatory setbacks in recent years, including a phase 3 clinical trial failure for one of its former leading candidates, VGX-3100. While INO-3107 shows clinical promise, ongoing litigation and regulatory uncertainty present material risks.
Top Insights
INO-3107 showed overall response rate (defined as 50%-100% reduction in surgeries) of 72% in year one, improving to 86% in year two.
Shareholders filed class action alleging materially false statements regarding manufacturing deficiency for the CELLECTRA device and INO-3107's regulatory prospects.
A competing FDA-approved RRP therapy could reach peak sales of about $1.1 billion, validating the market opportunity.
The Cellectra device complicates manufacturing and commercial rollout, as physicians and health insurers may hesitate given the extra administration step not yet proven in the real world.
Named Competitors
RRP Treatment — FDA-approved first therapy for recurrent respiratory papillomatosis, approved 2025
HPV Immunotherapies — Traditional HPV vaccine and immunotherapy programs
Recent Developments
(March 2026) Inovio CEO highlights INO-3107 BLA acceptance and FDA engagement ahead of October 30 PDUFA target date
(December 2025) FDA accepted Inovio's BLA for INO-3107 under standard review timeline for recurrent respiratory papillomatosis
(February 2026) Multiple class action lawsuits filed against Inovio regarding alleged false statements on device manufacturing and product prospects
Open the full interactive Inovio Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.